| pubmed-article:18685141 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18685141 | lifeskim:mentions | umls-concept:C0017661 | lld:lifeskim |
| pubmed-article:18685141 | lifeskim:mentions | umls-concept:C0035096 | lld:lifeskim |
| pubmed-article:18685141 | lifeskim:mentions | umls-concept:C0009429 | lld:lifeskim |
| pubmed-article:18685141 | lifeskim:mentions | umls-concept:C0032615 | lld:lifeskim |
| pubmed-article:18685141 | lifeskim:mentions | umls-concept:C0282440 | lld:lifeskim |
| pubmed-article:18685141 | lifeskim:mentions | umls-concept:C1096777 | lld:lifeskim |
| pubmed-article:18685141 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18685141 | pubmed:dateCreated | 2008-12-19 | lld:pubmed |
| pubmed-article:18685141 | pubmed:abstractText | Currently, several therapeutic protocols exist for IgA nephropathy (IgAN); results in slowing the progression to end-stage renal disease (ESRD) are variable, but approximately 30-40% of patients require replacement therapy (dialysis or renal transplantation) by 20 years from the onset. The adverse effects brought by the chronic assumption of drugs can be a potential limit. Actually, the most used therapies for IgAN are renin-angiotensin system blockers (RASB), glucocorticoids and immunosuppressive agents. Trials with polyunsaturated fatty acids (PUFA) in IgAN have been done since the first successful attempt by Hamazaki in 1984, resulting in alternate answers, but no trials have ever been done testing the efficacy of combined therapy with RASB and PUFA. | lld:pubmed |
| pubmed-article:18685141 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18685141 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18685141 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18685141 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18685141 | pubmed:issn | 1460-2385 | lld:pubmed |
| pubmed-article:18685141 | pubmed:author | pubmed-author:GambaroGiovan... | lld:pubmed |
| pubmed-article:18685141 | pubmed:author | pubmed-author:CostanziStefa... | lld:pubmed |
| pubmed-article:18685141 | pubmed:author | pubmed-author:FerraccioliGi... | lld:pubmed |
| pubmed-article:18685141 | pubmed:author | pubmed-author:FerraroPietro... | lld:pubmed |
| pubmed-article:18685141 | pubmed:author | pubmed-author:FulignatiPier... | lld:pubmed |
| pubmed-article:18685141 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18685141 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:18685141 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18685141 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18685141 | pubmed:pagination | 156-60 | lld:pubmed |
| pubmed-article:18685141 | pubmed:dateRevised | 2009-8-18 | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:meshHeading | pubmed-meshheading:18685141... | lld:pubmed |
| pubmed-article:18685141 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:18685141 | pubmed:articleTitle | Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. | lld:pubmed |
| pubmed-article:18685141 | pubmed:affiliation | Department of Nephrology, Catholic University of the Sacred Heart, Rome, Italy. manuel.ferraro@tiscali.it | lld:pubmed |
| pubmed-article:18685141 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18685141 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18685141 | lld:pubmed |
